Meso Scale Discovery (MSD) Electrochemiluminescence (ECL) Assay for Broad Range Multiplex Detection

Meso Scale Discovery Assay is a bioanalysis platform that utilizes electrochemiluminescence, unlike the colorimetric or chemiluminescent reaction in ELISA, as a signal detection technique. MSD ECL Assays are superior to traditional ELISA in many aspects, even as the various viable assay versions are quite like different types of ELISA. MSD Quick Plex 120 instrument applies the robust and sensitive electrochemiluminescence technology to quantitate single and multiple target analyte. MSD Assays enable accurate determination of analytes in complex biological matrices with improved throughput in a cost-effective and timely manner. Specifically, we can use MSD to analyze many clinically proven biomarkers, perform PK/TK analysis, and carry out ADA immunogenicity testing in a broad range of sample types such as blood, serum, and tissue, etc.

MSD ECL allows simultaneous multiplexing of up to 10 different analytes within the same well. Thus, the MSD platform requires 50-fold less sample than an ELISA method. Below, please see other crucial benefits of the Meso Scale Discovery technology –

  • Absolute quantitation, short processing time, and low sample requirement (~10µl)
    • High standardization from simple protocols resulting in superior inter-laboratory reproducibility
    • Less time/labor intensive for scalability to larger lots
    • Low sample volume from human, rodent (mice, rat) and non-rodent (NHP, dog) species
  • Higher sensitivity, better dynamic range, and reduced signal-to-noise ratio
    • Low analyte levels in small sample volumes
    • High/low abundance analytes (normal vs. elevated) within the same sample given large dynamic range
    • Limited matrix effect in serum, plasma, tissue culture media (TCM), and various other complex biological matrices
  • Ready-made single analyte and multiplex kits with excellent performance and lot-to-lot consistency
    • Fit-for-purpose MSD portfolio: 400+ MSD V-plex (pre-validated), U-plex (personalized multiplex), R-plex (not multiplexed), and S-plex (ultra-sensitive) assay
  • Most suitable to detect low-affinity anti-drug-antibodies (ADA)
  • Emission at ~620 nm solves any color quenching problems

MSD Assay: Electrode Plate Binding with Electrochemiluminescence Quantitation

MSD Assays utilize a carbon electrode plate surface for reagent binding and rely on electrochemiluminescence for ultra-sensitive antigen quantitation. These electrodes in the bottom of multi-array and multi-spot MSD plates can bind up to ten reagents simultaneously. Typically, these reagents bounded to the electrode plate are antigens or antibodies of interest. Below, please see the three most common MSD Assay –

Direct MSD Assay

In Direct Assay, the antigens link the plate and detection antibodies themselves. These direct binding immunoassays are useful when only one antibody is available.

Indirect MSD Assay

In Indirect Assay, these antigens connect the plate with the primary antibody that, in turn, attaches with the secondary detection antibody.

Sandwich MSD Assay

In sandwich assay, both the capture and detection antibodies bind to the antigen to form an antibody-antigen-antibody sandwich. Here, the capture antibody attaches itself to the bottom of the electrode plate. These sandwich immunoassays are useful for high specificity and assay sensitivity when a suitable antibody pair is readily available.

In the MSD-ECL platform, we use detection antibodies linked to SULFO-TAG labels that emit light on electric stimulation in a catalyst buffer. That said, only the tags near the electrified electrodes at the bottom of MSD microplates are excited by the detection process. The MSD instrument applies the electricity to trigger the oxidation-reduction reaction between SULFO-TAG labels and buffer to produce light that gets detected by the MSD CCD camera. Afterward, the Light intensity is measured precisely to quantify analyte levels. The Meso Scale platform operates on high concentrations of Tripropylamine as a catalyst for the reaction with Ruthenium to emit light with 620 nm wavelength.

Meso Scale Discovery Assay offered by NorthEast BioLab

Our veteran scientists gain a head start on your straightforward GLP studies that require full method validation from the precoated MSD V-plex plates as available. We are equally familiar with MSD U-plex, R-plex, and S-plex plates that allow maximum flexibility, no multiplexing, and higher sensitivity to design and build your custom assays, respectively.

Biomarker Assay: Cytokines, Chemokines, etc.

Northeast Biolab offers Biomarkers detection services in a broad range of sample matrices for mouse, rat, and human. MSD platform is suitable for identifying and analyzing trends in multiple cytokine profiles with better precision and higher sensitivity. We use MSD multiplex kits to quantify several analytes in a small volume sample, allowing simultaneous and cost-efficient measurement of cytokines and other biomarkers.

MSD V-PLEX™ Human Biomarker 54-Plex Kit

For a variety of biomarker testing, Northeast BioLab takes advantage of V-plex assays validated by MSD based on “fit-for-purpose principle, FDA guidance documents, and NCCLS documents. Here are our few selected Biomarker, Cytokines, and Chemokines assay:
CRP, Eotaxin, Eotaxin-3, FGF (basic), GM-CSF, ICAM-1, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-8 (HA), IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17B, IL-17C, IL-17D, IL-21, IL-22, IL-23, IL-27, IL-31, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, MIP-3α, PlGF, SAA, TARC, Tie-2, TNF-α, TNF-β, TSLP, VCAM-1, VEGF-A, VEGF-C, VEGF-D, VEGFR-1/Flt-1

Immunogenicity Assay

Immunogenicity assay has a vital role in identifying the human immune response produced against the large molecule drugs. MSD assays are widely recognized as the go-to, gold-standard platform for the majority of ADA assay run and immunogenicity testing. Here, our most common analysis formats include bridging immunogenicity assay and direct ADA assay. Generally, our sponsors are most interested in typical ADA assay parameters such as sensitivity, matrix tolerance, and free drug tolerance.

Pharmacokinetics (PK) Assay

Pharmacokinetics refers to the absorption, distribution, and elimination of the drug in the body over time. PK study examines how the body is responding throughout the drug life cycle. MSD technology allows us to perform smoother and faster PK analysis with higher sensitivity, broader dynamic range, and minimal matrix effects.

Potency Bioassay

These assays allow us to measure drug efficacy and determine the antibodies from patients inhibiting the drug activity in any biological system. MSD Assays can help assess the effectiveness of drug products.

Identity Bioassay

For drug manufacturers, the identity of the drug product is essential and must get tested. MSD serves as a diagnostic tool to help scientists identify the identity, purity, strength, and stability of your drug products.

Biomarker Assay List

Biomarker research, discovery, and qualification are pivotal in modern drug development from demonstrating proof-of-concept (POC) to establishing drug safety and efficacy in the clinic…

Superior MSD Assay by Veteran Team for High ROI CRO Partnership

NorthEast BioLab offers high precision singleplex and multiplex MSD Assay on our QuickPlex SQ120 platform in a broad range of sample matrices from Human, Mouse, Rat, and Canine samples. We have deep expertise in the GLP and GCP PK, TK, ADA Immunogenicity, and Biomarker assessments, including method development and validation from scratch. Additionally, we utilize assay kits validated by Meso Scale Discovery or in-house to quantify several analytes within a single low volume sample. These assays allow simultaneous comparison of the expression of relevant cytokines, chemokines, and other biomarkers in samples from diseased and healthy patients at different time intervals. Thus, MSD multiplexing maintains the accuracy, sensitivity, and performance while providing additional benefits such as short processing time, cost-savings, and targeting several analytes in a single sample. The ability to quantify compatible analytes in your MSD Assay while requiring no more than ~10 μl of sample is one of the benchmarks of our efficiency.

We are committed to provide our sponsors with high-quality bioanalytical services and support. Please contact us for any
COVID-19 related questions.